Isabel Preeshagul, DO, MBS, and colleagues share updates from across the lung cancer space as discussed in a recent State of the Science Summit.

Lung Cancer State of the Science Summit Recap

 on Lung Cancer chaired by Isabel Preeshagul, DO, MBS, she and colleagues highlight key takeaways from their presentations, which covered updates from across the lung cancer treatment paradigm. Preeshagul is a thoracic medical oncologist and assistant attending physician at Memorial Sloan Kettering Cancer Center.

Preeshagul discusses the clinical implications of 

data from the phase 3 ADRIATIC trial (NCT03703297)

, which showed that patients with limited-stage small cell lung cancer (LS-SCLC) whose disease has not progressed following platinum-based concurrent chemoradiotherapy experienced a median overall survival of 55.9 months (95% CI, 37.3-not evaluable) when treated with durvalumab (Imfinzi; n = 264) compared with 33.4 months (95% CI, 25.5-39.9) when given placebo (n = 266; HR, 0.73; 95% CI, 0.57-0.93; 

 = .0104). Based on these data, In August 2024, 

 to the supplemental biologics license application seeking the approval of durvalumab for the treatment of patients with LS-SCLC whose disease has not progressed following platinum-based concurrent chemoradiotherapy.

Next, Alissa J. Cooper, MD, a thoracic medical oncologist and assistant attending physician at Memorial Sloan Kettering Cancer Center, highlights the evolving understanding of the role of antibody-drug conjugates in the treatment of patients with non–small cell lung cancer (NSCLC). Cooper expands on the challenges posed in the clinical study of these agents and how biomarkers could help refine the understanding of which patients may benefit most from these agents.

Kathryn C. Arbour, MD, a thoracic medical oncologist and assistant attending physician at Memorial Sloan Kettering Cancer Center, then delves into the current treatment paradigm for patients with NSCLC harboring 

 G12C mutations. She details the prevalence of 

 mutations in this patient population and how ongoing research could build upon the targeted therapies available for those with 

Interested in attending a future State of the Science Summit or Institutional Perspectives in Cancer meeting? 

Videos

Lung Cancer State of the Science Summit Recap | Chaired by: Isabel Preeshagul, DO, MBS

Isabel Preeshagul, DO, MBS; Catherine Ann Shu, MD; and Ashish Saxena, MD, PhD, discuss the latest findings in small cell lung cancer based on studies that were presented during the 2021 ESMO Congress, 2021 World Conference on Lung Cancer, and 2021 ASCO Annual Meeting.


It’s Not a Small World for Small Cell Lung Cancer Treatment

Isabel Preeshagul, DO, MBS; Catherine Ann Shu, MD; and Ashish Saxena, MD, PhD, share insight on the data with novel targeted agents with impressive efficacy in patients with lung cancer, as seen at the 2021 ESMO Congress and the 2021 World Conference on Lung Cancer.

Living In a Targeted Therapy Revolution of NSCLC

Isabel Preeshagul, DO, MBS; Catherine Ann Shu, MD; and Ashish Saxena, MD, PhD, highlight results with immunotherapy in the neoadjuvant and stage IV setting in lung cancer that were presented at the 2021 World Conference on Lung Cancer and the 2021 ESMO Congress.

Neoadjuvant and Stage IV Immunotherapy Data Shaking Up Lung Cancer Paradigm

Good evening and welcome! Thank you for joining OncLive’s fourth episode of Thoracic Night Live, a program devoted to spotlighting the biggest topics in lung cancer and pivotal studies discussed at medical meetings throughout the year.

Live from New York City, I’m Dr Isabel Preeshagul, a medical oncologist at Memorial Sloan Kettering Cancer Center, and it’s great to be back on this program, this time as your host!

But tonight, it’s not just me. Virtually joining me is Dr Catherine Shu, an assistant professor of medicine and clinical director of the Thoracic Medical Oncology Service at Columbia University Herbert Irving Comprehensive Cancer Center, as well as Dr Ashish Saxena, an assistant professor of medicine at Weill Cornell Medical College and an assistant attending physician at the NewYork-Presbyterian Hospital.

Welcome both of you, and it’s an honor to share this virtual stage with you!

Tonight’s discussion is going to focus on some of the incredible findings that have read out in lung cancer from some recent medical meetings, including the 2021 World Conference on Lung Cancer and ESMO Congress. We’ll dig into some of the data as they relate to immunotherapy, targeted therapies, and even some exciting novel compounds across lung cancer subtypes.

Isabel Preeshagul, DO, MBS; Catherine Ann Shu, MD; and Ashish Saxena, MD, PhD, discuss breakthroughs in adjuvant immunotherapy in lung cancer from data presented at the 2021 ESMO Congress and 2021 World Conference on Lung Cancer. 

Adjuvant Immunotherapy Breakthroughs in Lung Cancer from ESMO 2021

Isabel Preeshagul, DO, MBS, a thoracic medical oncologist and assistant attending at Memorial Sloan Kettering Cancer Center, discusses the need for more information about using biosimilars when treating patients with cancer.

Preeshagul finds that using biosimilars can be challenging due to a lack of information regarding what biosimilar drugs have been approved and when they should be implemented in a patient’s treatment course.

In order to get more physicians to use or consider using these types of agents, Preeshagul suggests improving the educations surrounding biosimilars. There should be guidance to aid oncologists through the implementation of the biosimilar in practice, Preeshagul concludes.

Isabel Preeshagul, DO, MBS, discusses the need for more information about using biosimilars when treating patients with cancer.

Isabel Preeshagul, DO, MBS

Articles

Lung Cancer State of the Science Summit Recap | Chaired by: Isabel Preeshagul, DO, MBS

It’s Not a Small World for Small Cell Lung Cancer Treatment

Living In a Targeted Therapy Revolution of NSCLC

Neoadjuvant and Stage IV Immunotherapy Data Shaking Up Lung Cancer Paradigm

Adjuvant Immunotherapy Breakthroughs in Lung Cancer from ESMO 2021

Dr. Preeshagul on Education for Biosimilars in Oncology